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Abstract
Patients with Stage Ⅳ cholangiocarcinoma are cur-
rently not considered to be surgical candidates and 
are typically offered systemic chemotherapy. Recently, 
several novel systemic chemotherapy regimens have 
allowed an initially unresectable cholangiocarcinoma to 
be resectable. The aim of this article is to present the 
usefulness of adjuvant surgery in a case of advanced 
cholangiocarcinoma that was successfully treated 
with gemcitabine. A 72-year-old man was diagnosed 
with distal cholangiocarcinoma with liver metastases 
(cT2N0M1, Stage Ⅳ). He underwent metal stent place-
ment in the duodenum to alleviate jaundice. After 18 
courses of chemotherapy using gemcitabine without 
severe drug toxicities, a computed tomography scan 
showed that the liver metastases in S6 and S7 had 
disappeared. The patient underwent subtotal stomach-
preserving pancreaticoduodenectomy and lymph node 
dissection. The pathological stage was pT2N0M0, 
Stage ⅠB. The patient underwent 6 cycles of adjuvant 
chemotherapy using gemcitabine. The patient is alive 
and well 6 years and 9 mo after the diagnosis. 
© 2013 Baishideng. All rights reserved.
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Core tip: Patients with Stage Ⅳ cholangiocarcinoma are 
currently not considered to be surgical candidates and 
are typically offered systemic chemotherapy. Recently, 
several novel systemic chemotherapy regimens have 
allowed an initially unresectable cholangiocarcinoma 
to be resectable. In a patient with advanced extrahe-
patic cholangiocarcinoma, gemcitabine (GEM) induced 
a dramatic reduction of the tumor, which led to cura-
tive resection and a long-term survival of 6 years and 9 
mo. This result suggests the possibility of advantages 
of using GEM for the treatment of advanced cholan-
giocarcinoma, and GEM-based chemotherapy could be 
performed more often for unresectable cholangiocarci-
nomas.
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INTRODUCTION
Cholangiocarcinoma continues to exhibit poor survival 
rates compared with other gastrointestinal malignan-
cies[1-4]. Most cholangiocarcinoma patients are not surgical 
candidates. Patients with Stage Ⅳ cholangiocarcinoma 
are currently inoperable and are typically offered systemic 
chemotherapy. The most promising approaches involve 
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the use of  single agents such as gemcitabine (GEM), 
which has been shown to be effective against cholan-
giocarcinoma in phase Ⅱ trials[5-7]. In these trials, the 
response rates for GEM ranged from 8% to 36%, and 
the overall survival (OS) ranged from 6.3 to 16 mo. We 
describe a rare case of  stage Ⅳ cholangiocarcinoma with 
liver metastases that was initially deemed unresectable 
and became resectable after GEM chemotherapy and 
showed a favorable outcome.
CASE REPORT
The patient was a 72-year-old man referred from a local 
hospital complaining of  jaundice. The laboratory data on 
admission showed the following elevated values: total bil-
irubin (T-bil), 6.2 mg/dL (normal range, 0.2-1.2 mg/dL); 
lactic acid dehydrogenase, 243 U/L (124-232 U/L); alka-
line phosphatase 354 U/L (120-320 U/L); and γ-glutamyl 
transpeptidase, 181 U/L (5-55 U/L). All the tumor 
markers tested were within the normal limits: carcinoem-
bryonic antigen (CEA), 2.3 ng/mL (normal range, < 5.0 
ng/mL), and carbohydrate antigen 19-9, 12.0 U/mL (< 
37 U/mL). Abdominal computed tomography (CT) and 
ultrasonography showed mild dilatation of  the common 
bile duct and bilateral dilation of  the intrahepatic bile 
ducts. Abdominal computed tomography angiography 
(CTA) detected wall thickening in the distal common bile 
duct, and the lesion was enhanced by contrast (Figure 1). 
CT and CTA showed two liver metastases, which mea-
sured 8 mm (S6) and 8 mm (S7) in diameter (Figure 2). 
According to the Union Internationale Contre le Cancer 
(UICC) guidelines, the patient was diagnosed with lower 
cholangiocarcinoma (cT2N0M1, Stage Ⅳ)[8]. 
The patient underwent successful placement of  a self-
expandable metal duodenal stent to relieve jaundice. The 
patient received a total of  18 cycles of  GEM. GEM was 
administered intravenously at a dose of  800 mg/m2 per 
day on days 1, 8, and 15 in a 28-d cycle. Adverse events 
were graded according to the National Cancer Institute 
Common Toxicity Criteria Grading System (Version 2.0, 
April 1999)[9]. Severe drug toxicities (grade 3 or 4) were 
not observed.
After 18 cycles of  chemotherapy, CT showed that the 
two liver metastases in S6 and S7 disappeared. The tumor 
was clinically downstaged to Stage ⅠB (cT2N0M0).
Four weeks after the completion of  chemotherapy, 
the operation was successfully performed. Peritoneal 
lavage cytology demonstrated no cancer cells in the ab-
dominal cavity. No microscopic invasion of  the resected 
bile duct stump was observed in an intraoperative frozen 
specimen. The patient underwent curative resection con-
sisting of  SSPPD with D2 lymphadenectomy without 
resecting any other organs. 
Tumor cells were detected in the distal bile duct 
upon microscopic examination (Figure 3). According 
to the UICC guidelines, the pathological classification 
of  the tumor was cT2N0M0 Stage ⅠB. The patient was 
discharged on postoperative day 61 in good condition. 
The patient subsequently received six cycles of  adjuvant 
GEM chemotherapy similar to the preoperative regimen. 
The patient is alive at 6 years and 9 mo after the diagnosis 
and 5 years after the surgery.
DISCUSSION
The prognosis of  patients with cholangiocarcinoma is 
poor, with a five-year survival rate of  approximately 25% 
to 55%[1-4]. To overcome this clinical challenge, several 
strategies, including adjuvant chemotherapy, adjuvant 
radiotherapy, and adjuvant chemoradiotherapy have been 
considered for treating cholangiocarcinoma[10-13]. Few 
randomized clinical trials have evaluated the utility of  
adjuvant therapy following R0 resection of  cholangio-
carcinoma, and most of  the current studies are small and 
retrospective. Therefore, no standard adjuvant modalities 
have been universally adopted for the treatment of  chol-
angiocarcinoma, and the role of  chemotherapy for un-
resectable cholangiocarcinoma has not been established. 
Although there has been no standard chemotherapy for 
cholangiocarcinoma, GEM has been the most actively 
used agent against cholangiocarcinoma. We treated a 
patient with advanced extrahepatic cholangiocarcinoma 
with liver metastases. The patient showed a dramatic 
response to GEM, which led to curative resection and 
long-term survival of  more than 6 years. GEM may be 
an effective chemotherapeutic agent for treating cholan-
giocarcinoma, and a randomized clinical trial needs to be 
performed.
The feasibility of  adjuvant surgery for cholangiocar-
cinoma has not been determined. Recently, in colorectal, 
gastric, and pancreatic cancer, several authors have re-
ported “conversion surgery” or “adjuvant surgery”[14-16]. 
Suzuki et al[14] demonstrated that adjuvant surgery was 
effective in 20 advanced gastric cancer patients (Stage 
Ⅳ) based on liver or distant lymph node metastasis. The 
overall survival of  patients in the partial response and 
curative resection groups was prolonged. The survival 
of  patients with H or N factor was also prolonged when 
they received curative surgery. However, the survival of  
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Figure 1  Abdominal computed tomography angiography image of the 
common bile duct. Thickening of the wall of the distal common bile duct, which 
enhances with contrast, was observed (arrowhead).
patients with P factor was not prolonged. Locally ad-
vanced pancreatic cancer may be a good indication for 
adjuvant surgery after sustained favorable responses to 
chemotherapy, even in patients with initially unresect-
able disease[16]. In 2013, Kato et al[17] reported that eight 
patients with initially unresectable advanced biliary tract 
cancer who underwent adjuvant surgery had significantly 
longer survival than 14 patients who were unable to un-
dergo surgery. Of  the eight patients in the surgery group, 
four patients had gallbladder carcinoma and four patients 
had intrahepatic cholangiocarcinoma. To our knowledge, 
from 1983 to 2013, in the field of  bile duct cancer, only 
16 cases in nine reports underwent adjuvant surgery, 
including the cases in the report[17-25] (Table 1). Of  the 
16 patients, 10 patients received GEM, 3 received S-1, 2 
received GEM and S-1, 1 received GEM combined with 
cisplatin and fluorouracil, and 1 received cisplatin/inter-
feron α-2b/doxorubicin/fluorouracil-combination che-
motherapy. None of  the 16 cases involved extrahepatic 
cholangiocarcinoma. To the best of  our knowledge, this 
is the first report of  adjuvant surgery for extrahepatic 
cholangiocarcinoma.
Medical oncologists and surgeons have identified sur-
gical candidates among patients with initially unresectable 
colorectal and gastric cancer who responded favorably to 
multimodal treatment[14,15]. In some cases, the addition of  
surgery resulted in increased long-term survival. Surgical 
resection coupled with multimodal treatment is called 
“adjuvant surgery.” Surgical resection can be classified as 
curative (no evidence of  remaining disease after surgery) 
or palliative (remaining disease after surgery). Therefore, 
adjuvant surgery aims to be curative and not palliative af-
ter the response to chemotherapy[14]. 
In a strategy involving adjuvant surgery, adjuvant che-
motherapy is considered necessary after the operation. In 
our patient, the liver metastases showed a surprising com-
plete response without severe toxicity after GEM chemo-
therapy. Additionally, the patient received adjuvant che-
motherapy using GEM as an outpatient and developed 
no adverse reactions. In previous phase Ⅱ studies using 
single-agent GEM, major adverse reactions included 
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Figure 2  Abdominal computed tomography and computed tomography angiography images at two different levels are shown. A: Computed tomography (CT) 
showed a low-density mass measuring 8 mm in diameter located in segment 7 of the liver (arrowhead); B: CT showed a low-density mass measuring 8 mm in diam-
eter in segment 6 (arrowhead); C: Computed tomography angiography (CTA) demonstrated an enhancing mass lesion at the same location as in Figure 2A (arrowhead); 
D: CTA demonstrated an enhancing mass lesion at the same location as in Figure 2B (arrowhead). 
Figure 3  Histopathologic appearance of the cholangiocarcinoma (hema-
toxylin and eosin, × 200). Tumor cells were detected in the distal bile duct on 
microscopic examination. 
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Cholangiocarcinoma: thirty-one-year experience with 564 
patients at a single institution. Ann Surg 2007; 245: 755-762 
[PMID: 17457168 DOI: 10.1097/01.sla.0000251366.62632.d3]
3 Sasaki R, Takahashi M, Funato O, Nitta H, Murakami M, 
Kawamura H, Suto T, Kanno S, Saito K. Prognostic signifi-
cance of lymph node involvement in middle and distal bile 
duct cancer. Surgery 2001; 129: 677-683 [PMID: 11391365 DOI: 
10.1067/msy.2001.114555]
4 Oshiro Y, Sasaki R, Kobayashi A, Murata S, Fukunaga K, 
Kondo T, Oda T, Ohkohchi N. Prognostic relevance of the 
lymph node ratio in surgical patients with extrahepatic 
cholangiocarcinoma. Eur J Surg Oncol 2011; 37: 60-64 [PMID: 
21094016 DOI: 10.1016/j.ejso.2010.10.011.]
5 Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, 
Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer 
W. Phase II trial of two-weekly gemcitabine in patients with 
advanced biliary tract cancer. Ann Oncol 2001; 12: 183-186 
[PMID: 11300321]
6 Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, 
Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima 
E, Papadoniou N, Karatzas G, Papalambros E. Weekly gem-
citabine for the treatment of biliary tract and gallbladder can-
cer. Invest New Drugs 2004; 22: 193-198 [PMID: 14739669 DOI: 
10.1023/B: DRUG.0000011797.09549.53]
7 Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito 
S, Saito H, Tsuyuguchi T. Phase II study of single-agent gem-
citabine in patients with advanced biliary tract cancer. Cancer 
Chemother Pharmacol 2006; 57: 647-653 [PMID: 16142487 DOI: 
10.1007/s00280-005-0095-3]
8 Union Internationale Contre le Cancer. TNM classification of 
malignant tumours. 7th ed. New York, NY: Wiley-Liss, 2009
9 National Institute of Health. NCI: Common Toxicity Crite-
ria, Version 2.0. Available from: URL: http://ctep.info.nih.
gov/reporting/ctc.html
10 Gerhards MF, van Gulik TM, González González D, Rauws 
EA, Gouma DJ. Results of postoperative radiotherapy for 
resectable hilar cholangiocarcinoma. World J Surg 2003; 27: 
173-179 [PMID: 12616432 DOI: 10.1007/s00268-002-6434-1]
11 Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, 
Kashiwagi H, Otsuka M, Fukao K. Benefits of adjuvant 
radiotherapy after radical resection of locally advanced 
main hepatic duct carcinoma. Int J Radiat Oncol Biol 
Phys 2000; 46: 581-587 [PMID: 10701737 DOI: 10.1016/
S0360-3016(99)00472-1]
12 Kelley ST, Bloomston M, Serafini F, Carey LC, Karl RC, Zer-
vos E, Goldin S, Rosemurgy P, Rosemurgy AS. Cholangiocar-
neutropenia, leukopenia, and anemia were observed with 
little severe toxicity[5-7]. The results suggests that GEM is 
suitable for outpatients because of  its mild toxicity.
The UK ABC-02 study defined the standard of  care 
for unresectable advanced biliary tract cancer[26]. Valle et 
al[26] reported that cisplatin with GEM (GEMC) was as-
sociated with a significant survival advantage compared 
with GEM alone. The median OS was 11.7 mo for 
GEMC and 8.1 mo for GEM alone[26]. A Japanese trial 
of  83 patients using the same treatment regimens as UK 
ABC-02 showed the median survival and overall response 
rate of  GEMC vs GEM alone were 11.2 mo vs 7.7 mo 
and 19.5% vs 11.9%, respectively. These results were con-
sistent with the results of  the UK ABC-02 study. GEMC 
was found to be effective and well tolerated, which indi-
cates that it could also be a standard regimen for Japanese 
patients[27].
In conclusion, in a patient with advanced extrahepat-
ic cholangiocarcinoma, GEM induced a dramatic reduc-
tion of  the tumor, which led to curative resection. The 
patient was still living 6 years and 9 mo after the study. 
The results suggest possible advantages of  using GEM 
for the treatment of  advanced cholangiocarcinoma. 
GEM-based chemotherapy could be more commonly 
administered for unresectable cholangiocarcinoma. Fur-
thermore, “adjuvant surgery” (i.e., R0 resection) may 
significantly contribute to curing cholangiocarcinoma. 
An evidence-based consensus should be developed on 
potentially resectable cholangiocarcinoma with liver me-
tastases in each hospital.
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